| Literature DB >> 35394134 |
Lélia Lilianna Borges de Sousa Macedo1, Flavia Tasmin Techera Antunes2, Willyane de Andrade Alvarenga3, Mara Cristina Carvalho Batista3, Mayara Storel Beserra de Moura3, Mariane Nunes Lima Farias4, Emanuelle Sistherenn Caminski5, Eliane Dallegrave5, Ivana Grivicich1, Alessandra Hübner de Souza1.
Abstract
Curcumin has protective actions in neuropsychiatric disorders, acting as a neuroprotective agent. As a first approach, the study aimed at a systematic review of the potential effects of curcumin on cognitive performance for attention-deficit-hyperactivity disorder (ADHD). This research was carried out in the databases of PubMed, Embase, SciELO, the Cochrane Central Register of Controlled Trials (CENTRAL), the Web of Science, and the Grey literature. Upon discovering the scarcity of relevant studies, and knowing that curcumin might have an ADHD hyperactive and anxious behavior, the study proposed to evaluate the effects of curcumin in an ADHD phenotype of spontaneously hypertensive Wistar rats (SHR). No studies were found that related to curcumin and ADHD. Fifteen SHRs were then divided into separate groups that received water (1 mg/kg/day), curcumin (50 mg/kg/day), or methylphenidate (1 mg/kg/day) for 42 days. Behavioral tests to assess activity (Open Field Test), anxiety and impulsivity (Elevated Plus-Maze, and Social Interaction), and memory (Y-Maze, and the Object Recognition Test) were all performed. The animals that were treated with curcumin showed less anxious and hyperactive behavior, as seen in the Open Field Test and the Social Interaction Test. Anxious behavior was measured by the EPM and was not modulated by any treatment. The results of the Y-Maze Test demonstrated that curcumin improved spatial memory. In the Object Recognition Test, neither the short nor the long-term memory was improved. The treatments that were used in this study beneficially modulated the anxious and hyperactive behavior of the SHR.Entities:
Keywords: Anxious behavior; Hyperactivity; Neurodevelopmental disorder; Spontaneously hypertensive rats
Mesh:
Substances:
Year: 2022 PMID: 35394134 DOI: 10.1007/s00210-022-02236-0
Source DB: PubMed Journal: Naunyn Schmiedebergs Arch Pharmacol ISSN: 0028-1298 Impact factor: 3.000